Real-World Characteristics and Outcome of Patients Treated With Single-Agent Ibrutinib for Chronic Lymphocytic Leukemia in Spain (IBRORS-LLC Study) - Abrisqueta P; Loscertales J; Terol MJ; Ramírez Payer Á; Ortiz M; Pérez I; Cuellar-García C; Fernández de la Mata M; Rodríguez A; Lario A; Delgado J; Godoy A; et al. (Clinical Lymphoma Myeloma & Leukemia, 2021)